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Abstract: The placental epigenome regulates processes that affect placental and fetal development,
and could be mediating some of the reported effects of maternal choline supplementation (MCS) on
placental vascular development and nutrient delivery. As an extension of work previously conducted
in pregnant mice, the current study sought to explore the effects of MCS on various epigenetic
markers in the placenta. RNA and DNA were extracted from placentas collected on embryonic
day 15.5 from pregnant mice fed a 1X or 4X choline diet, and were subjected to genome-wide
sequencing procedures or mass-spectrometry-based assays to examine placental imprinted gene
expression, DNA methylation patterns, and microRNA (miRNA) abundance. MCS yielded a higher
(fold change = 1.63–2.25) expression of four imprinted genes (Ampd3, Tfpi2, Gatm and Aqp1) in the
female placentas and a lower (fold change = 0.46–0.62) expression of three imprinted genes (Dcn, Qpct
and Tnfrsf23) in the male placentas (false discovery rate (FDR) ≤ 0.05 for both sexes). Methylation
in the promoter regions of these genes and global placental DNA methylation were also affected
(p ≤ 0.05). Additionally, a lower (fold change = 0.3; Punadjusted = 2.05× 10−4; FDR = 0.13) abundance of
miR-2137 and a higher (fold change = 1.25–3.92; p < 0.05) expression of its target genes were detected
in the 4X choline placentas. These data demonstrate that the placental epigenome is responsive
to maternal choline intake during murine pregnancy and likely mediates some of the previously
described choline-induced effects on placental and fetal outcomes.
Keywords: choline; placenta; imprinted genes; DNA methylation; microRNA
1. Introduction
Epidemiological studies have shown that an adverse in utero environment is associated with
a higher risk of developing obesity, metabolic syndrome, cardiovascular disease and other chronic
diseases later in life [1–3]. These findings have led to the fetal programming hypothesis, which suggests
that the developing fetus will generate an adaptive response to the suboptimal prenatal environment
in order to increase its survival. This adaptive response involves changing the development of
the placenta [4] as well as the fetus and its organs, with lasting effects on their functioning [3].
Although there is a growing body of evidence in support of this hypothesis, the molecular mechanisms
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mediating the programming phenomenon are less clear. One proposed mechanism linking prenatal
exposure to later health outcomes is the modulation of gene expression via epigenetic processes.
Many epigenetic processes are involved in the regulation of gene expression. The most widely
studied process is DNA methylation, the addition of methyl groups to the cytosine residues of
cytosine-phosphate-guanine (CpG) dinucleotides situated within the regulatory regions of some
genes (e.g., the promoter and the differential methylation region). One group of genes known to be
regulated by DNA methylation is the imprinted genes, which are expressed according to parental
origin [5,6]. Many of the imprinted genes are expressed in the placenta where they synthesize proteins
that control the cell cycle, cell signaling and vascularization, and the uptake, utilization and storage
of nutrients [5,6]; all of which can affect placental nutrient supply efficiency. Aberrant expression of
these imprinted genes, including IGF2, H19 and TFPI2, in the human placenta alters fetal growth and
affects birth weight [5,7]. The expression of placental imprinted genes may also serve as a biomarker
for future health outcomes, such as infant neurodevelopment and bone health at the age of four [8,9].
Another epigenetic mechanism that has received increased attention in recent years involves
the microRNAs (miRNAs). These are small non-coding RNA molecules with 19–24 nucleotides
that post-transcriptionally regulate gene expression [10]. Specifically, miRNA base-pairs with its
mRNA targets in a sequence-specific manner to trigger mRNA transcript degradation or translational
repression [10,11]. As such, expression of a miRNA will reduce the expression of its mRNA targets.
The placenta produces many miRNAs, and their target genes are involved in cell proliferation,
apoptosis, invasion and angiogenesis [11,12], which are essential to normal placental morphological
and vascular development. Some miRNAs also regulate immune cell development at the maternal–fetal
interface and mediate the immune response and maternal tolerance to the fetus [12]. Given their roles
in many aspects of placental development and function, it is not surprising that miRNA dysregulation
is associated with pregnancy disorders that impair fetal growth [10,13–15].
Choline is an essential micronutrient involved in one-carbon metabolism. Its oxidative derivative,
betaine, converts homocysteine to methionine, which is used to generate S-adenosylmethionine (SAM),
the universal methyl donor for many cellular methylation reactions including DNA methylation,
which can exert lasting effects on gene expression and physiological processes [16]. Our previous
studies indicated that maternal 4X choline supplementation during normal murine pregnancy
improves placental vascularization and perfusion [17,18] and enhances placental nutrient supply [19]
and early fetal growth [20]. Given the roles of imprinted genes, DNA methylation, and miRNAs
in these placental and fetal outcomes (as described above), we sought to test the hypothesis that
maternal choline supplementation would alter the placental epigenome during normal murine
pregnancy. We tested this hypothesis using placental tissues that had been previously collected
at embryonic day (E) 15.5—a time when the placenta reaches its maximal size and the fetus is rapidly
growing [21,22]—from dams receiving 1X or 4X choline supplementation.
2. Materials and Methods
2.1. Animals and Diets
This study was an extension of an animal feeding study where we examined the impact of
maternal choline supplementation on placental vascularization and nutrient transport system [17,19].
Briefly, adult non-Swiss Albino mice (Harlan) were purchased and used as a breeding colony. The mice
had ad libitum access to commercial rodent chow and water, and were housed in microisolator cages
(Ancare) in an environmentally-controlled room (22–25 ◦C, 70% humidity) with a 12-h light–dark
cycle. Offspring from the breeding colony were fed a 1X choline diet (1.4 g choline chloride/kg
diet; Dyets #103345) subsequent to weaning at 3 weeks old. Five days prior to mating, female mice
were randomized to one of three diets: 1X choline, 2X choline (2.8 g choline chloride/kg diet; Dyets
#103346), or 4X choline (5.6 g choline chloride/kg diet; Dyets #103347). Presence of a vaginal plug
was defined as E0.5. Pregnant female mice continued their diet until they were euthanized using
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carbon dioxide at one of four time points: E10.5, E12.5, E15.5 or E18.5. The present study used the
tissues collected at E15.5 from dams fed the 1X choline and 4X choline diets (n = 3 dams per group,
per fetal sex; total n = 12 dams). To ensure statistical independence, only one placenta (either male
or female) from each dam was used for each experiment. Each placenta, therefore, was considered
to be an experimental unit. The 4X choline was chosen because our previous findings indicated a
pronounced effect of this dosage on placental development and function [17,19], while E15.5 was
chosen because it represents the time when the placenta reaches its maximal size and the fetus is
rapidly growing [21,22]. To minimize maternal decidual contamination, the maternal decidua was
carefully trimmed and removed during the dissection. The placental disks that were used for the
experiments were washed multiple times with phosphate-buffered saline (PBS) to ensure that maternal
blood was completely removed before they were weighed, flash frozen in liquid nitrogen and stored
at −80 ◦C. The fetuses were also collected and weighed during the dissection and were flash frozen
in liquid nitrogen before storage at −80 ◦C. The data on fetal weight, placental weight and placental
efficiency were reported in [19]. All animal protocols were approved by the Institutional Animal Care
and Use Committees at Cornell University (the approval number is 2001-0034) and were conducted in
accordance with the Guide for the Care and Use of Laboratory Animals.
2.2. Fetal Sex Genotyping
Fetal DNA was extracted using the DNeasy blood and tissue kit (Qiagen, Germantown, MD,
USA, Catalog #: 69506), and fetal sex was determined by PCR for the Sry gene, using forward
5′-TGGGACTGGTGACAATTGTC-3′ and reverse 5′-GAGTACAGGTGTGCAGCTCT-3′ primers.
2.3. Placental RNA Extraction
Total RNA was extracted from the placentas using Trizol (Thermo Fisher, Waltham, MA, USA,
Catalog #: 15596026) according to the manufacturer’s instructions with the following modifications:
(i) an extra chloroform extraction step of the aqueous layer after the first phase separation; (ii) addition
of 1 µL Glyco-blue (Thermo Fisher, Waltham, MA, USA, Catalog #: AM9515) before the isopropanol
precipitation; and (iii) two washes of the RNA pellet with 75% ethanol. RNA concentration and
purity were determined using a NanoDrop spectrophotometer (Thermo Fisher, Waltham, MA, USA).
RNA integrity and presence of small RNAs (<<200 nucleotides) were determined with a Fragment
Analyzer (Advanced Analytical, Ankeny, IA, USA).
2.4. Placental mRNA Sequencing and Data Analysis
The following procedures were conducted by the Cornell RNA Sequencing Core (Ithaca, NY, USA).
NEBNext Ultra Directional RNA Library Prep Kit (New England Biolabs, Ipswich, MA, USA, Catalog
#: E7420) was used to make polyA+ RNAseq libraries, using 1 µg total RNA input. RNAseq libraries
were sequenced on an Illumina NextSeq500 with single-end 81 nt reads to generate an average of 44 M
(min 37 M) reads per sample. Raw reads were trimmed and filtered with cutadapt [23] (parameters: -m
20 -q 20 -a AGATCGGAAGAGCACACGTCTGAACTCCAGTC –match-read-wildcards) to remove
adaptor and low quality bases. After processing, reads were mapped to the reference mouse
transcriptome (UCSC mm10) with Tophat (Version 2.0) [24] (parameters: -G <UCSC_mm10.gtf>
–no-novel-juncs –library-type fr-firststrand). FPKM (fragments per kilobase of transcript per million
mapped reads) values were generated, and statistical analyses (both females and males together as well
as separately) were performed using Cuffdiff (Cufflinks, Version 2.2) [25] (parameters: –library-type
fr-firststrand). Genes were considered to have significantly different expression when the false
discovery rate (FDR) was less than 0.2. Differentially-expressed imprinted genes were identified
as listed on the MRC Harwell Imprinting Webpages (http://www.har.mrc.ac.uk/research/genomic_
imprinting/) [26]. RNAseq data have been deposited in the National Center for Biotechnology
Information (NCBI)’s Gene Expression Omnibus (GEO) and are accessible through the GEO Series
accession number, GSE111296 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111296).
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2.5. Placental miRNA Sequencing and Data Analysis
The following procedures were conducted by the Cornell RNA Sequencing Core (Ithaca, NY,
USA). Libraries were made using the NEBNext Small RNA Library Prep Kit (New England Biolabs,
Ipswich, MA, USA, Catalog #: E7330) using 1 µg total RNA input and were size-selected for
18–30 nt inserts on polyacrylamide gels. Small RNA libraries were sequenced on an Illumina
HiSeq2500 with single-end 50 nt reads to generate an average of 12 M (min 7.5 M) reads per
sample. Raw reads were trimmed and filtered with cutadapt [23] (parameters: -m 10 -q 20 -a
AGATCGGAAGAGCACACGTCTGAACTCCAGTC –match-read-wildcards) to remove adaptor and
low quality bases. Processed reads were mapped to mature mouse miRNAs (miRBase, Version 21)
using miRDeep2 [27]. One female placental sample in the 1X choline group had a lower
miRNA-mapped read frequency, suggesting possible sample degradation. Therefore, this sample
was excluded from subsequent analyses. Small RNA sequencing data have been deposited in NCBI’s
Gene Expression Omnibus and are accessible through GEO Series accession number GSE111296
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111296).
Statistical testing of differential expression of the miRNAs was determined in EdgeR
using a generalized linear model with a negative binomial distribution and filtering of CPM
(counts per million) > 1 in at least 1 sample. Predicted mRNA targets of the most differentially-
expressed miRNA were identified using TargetScan (Version 7.1) [28]. Strong targets were defined,
in a similar manner to other investigations, with a context++ score ≤ −0.2, where a more negative
score indicates greater repression [29,30]. Gene ontology was conducted for the mRNA targets using
PANTHER Overrepresentation Test (Version 11.1) [31,32]. The expression of each of the mRNA targets
identified from TargetScan was obtained from the mRNA sequencing dataset.
2.6. Placental DNA Extraction
Genomic DNA was extracted from the placenta using the DNeasy blood and tissue kit (Qiagen,
Germantown, MD, USA, Catalog #: 69506), with the addition of RNase A (Qiagen, Germantown, MD,
USA, Catalog #: 19101) to remove any co-purified RNA. DNA concentration and purity were evaluated
using a NanoDrop spectrophotometer.
2.7. Promoter Methylation Assay and Data Analysis
A site-specific methylation analysis was conducted to determine the methylation patterns
in the promoter regions of the differentially-expressed placental imprinted genes identified from
the mRNA sequencing dataset. This assay was performed by the Cornell Epigenomics Core
(New York, NY, USA) using the EpiTyper MassArray System (Agena Bioscience, San Diego, CA,
USA), as described previously [33]. Briefly, genomic DNA was bisulfite-treated using the EZ DNA
methylation kit (Zymo Research, Irvine, CA, USA, Catalog #: D5001). PCR amplification was performed
to amplify the regions of interest using bisulfite-treated DNA and T7-promoter tagged primers
(Supplemental Table S1), followed by Shrimp Alkaline Phosphatase (SAP) treatment and in vitro
transcription. The resulting products were then loaded onto a SpectroCHIP Array and analyzed by
a matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (MALDI-TOF MS).
Percent methylation of the cytosine residues at each CpG unit, which may contain more than one
CpG site, was obtained from the EpiTyper software. CpG units in the promoter region of each gene
were labelled alphabetically with letters. For quality control purposes, CpG units that could not
be reliably detected by EpiTyper (e.g., a high signal to noise ratio, a high or low mass, duplication,
inadequate number of replicates) were excluded from further analyses (Supplemental Table S2) [34].
The methylation level at each individual CpG unit as well as the average methylation of all the
CpG units for each gene were analyzed using one-way ANOVA, where p ≤ 0.05 indicated statistical
significance. Data are presented as means with 95% confidence intervals. All the statistical analyses
were done using SPSS software (Version 23, IBM, Armonk, NY, USA).
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2.8. Global DNA Methylation Assay and Data Analysis
Global DNA methylation was measured using LC-MS/MS (Thermo Fisher, Waltham, MA, USA),
as described previously, with modifications based on our instrumentation [34,35]. Briefly, 300 ng
genomic DNA was digested with nuclease P1 (Sigma-Aldrich, St. Louis, MO, USA, Catalog #: N8630),
followed by digestion with phosphodiesterase 1 (Sigma-Aldrich, St. Louis, MO, USA, Catalog #: P3243)
and digestion with alkaline phosphatase (Sigma-Aldrich, St. Louis, MO, USA, Catalog #: P4252).
Samples were diluted with 0.1% formic acid in water and injected into the instrument for analysis.
Global methylation is presented as a percentage of the amount of 5-methyl-2′-deoxycytidine (5mdC)
relative to the total amount of cytosine (i.e.,: 5mdC/(dC + 5mdC)). Data were first analyzed without
stratification by fetal sex and then separately for each fetal sex using one-way ANOVA. Statistical
significance was defined as p ≤ 0.05. Data are presented as means with 95% confidence intervals.
All the statistical analyses were done using SPSS software (Version 23, IBM, Armonk, NY, USA).
3. Results
3.1. Placental Imprinted Gene Expression
Supplementation during pregnancy with 4X maternal choline altered (FDR < 0.2) the
placental expression of 131 genes, 28 of which were common to both male and female placentas.
Because placental gene expression exhibits sexual dimorphism [36], we also analyzed the male and
female placentas separately. In the female placentas, 4X (versus 1X) choline decreased the expression
of 44 genes (FDR < 0.2) and increased the expression of 143 genes (FDR < 0.2). Among these 187 genes
exhibiting differential expression, three were known imprinted genes: Tfpi2 (fold change = 2.17),
Ampd3 (fold change = 1.63) and Gatm (fold change = 1.65) (Table 1). Furthermore, Aqp1, a recently
suggested placenta-specific imprinted gene [37], was also affected by 4X choline supplementation
(fold change = 2.25) (Table 1). In the male placentas, 4X (vs. 1X) choline decreased the expression of
79 genes (FDR < 0.2) and increased the expression of 62 genes (FDR < 0.2). Among these 141 genes
affected by 4X choline, three were known to be imprinted genes: Qpct (fold change = 0.46), Dcn
(fold change = 0.58) and Tnfrsf23 (fold change = 0.62) (Table 2). It is worth noting that all these placental
imprinted genes remained statistically significant with a lower FDR threshold (e.g., FDR < 0.1).
Regression analyses indicated positive correlations of the imprinted genes expression in the male
placentas with the weight of the male placentas (Qpct: β = 0.00079, p = 0.046; Dcn: β = 0.000049,
p = 0.01; Tnfrsf23: β = 0.0003, p = 0.039). Non-significant associations were also detected between
these imprinted genes and the efficiency of the male placentas (Dcn: β = −0.00061, p = 0.09; Tnfrsf23:
β = −0.0041, p = 0.078).
Table 1. Differentially-expressed imprinted genes in the female placentas in response to 4X versus 1X
maternal choline supplementation 1.
Gene Symbol Gene Name FoldChange
False Discovery Rate
(FDR) Value
Aqp1 a aquaporin 1 2.25 0.009
Tfpi2 b tissue factor pathway inhibitor 2 2.17 0.009
Ampd3 b adenosine monophosphate deaminase 3 1.63 0.009
Gatm b glycine amidinotransferase 1.65 0.054
1 Data were derived from an RNA-sequencing dataset, and statistical analysis was performed using Cuffdiff
(Cufflinks, Version 2.2) [25]. Genes with FDR < 0.2 were considered to have significantly different expression;
a Imprinted gene identified by Guo et al. [37]; b Imprinted genes listed on the MRC Harwell Imprinting
Webpages [26].
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Table 2. Differentially-expressed imprinted genes in the male placentas in response to 4X versus 1X
maternal choline supplementation 1.
Gene Symbol Gene Name Fold Change FDR Value
Qpct glutaminyl cyclase 0.46 0.012
Dcn decorin 0.58 0.012
Tnfrsf23 tumor necrosis factor receptor superfamily, member 23 0.62 0.012
1 Data were derived from an RNA-sequencing dataset and statistical analysis was performed using Cuffdiff
(Cufflinks, Version 2.2) [25]. Genes with FDR < 0.2 were considered to have significantly different expression. All the
imprinted genes were identified as listed on the MRC Harwell Imprinting Webpages [26].
3.2. Placental Gene Promoter Methylation
Because promoter DNA methylation is frequently involved in regulating gene transcription,
promoter methylation patterns of the differentially-expressed imprinted genes were examined. In the
female placentas, Aqp1 had eight CpG units that met our quality control criteria and were analyzed.
Compared to 1X choline, 4X choline supplementation yielded lower (p = 0.026) methylation of CpG
unit M in the promoter region of Aqp1, but had no effects on the other CpG units. For Tfpi2, three CpG
units in the promoter region met our quality control criteria and were included in the final analysis.
Although the changes in the methylation of each individual CpG unit did not achieve statistical
significance, the average CpG methylation in the promoter region was significantly lower (p = 0.009) in
response to 4X choline supplementation (vs. 1X choline). For Gatm, among the six CpG units examined
in this study, the methylation of CpG unit Z was three times higher (p = 0.009) in the female placentas
of the 4X choline group than those of the 1X choline group. None of the other CpG units in the Gatm
promoter were significantly affected by 4X choline supplementation, nor was methylation altered in
the promoter region of Ampd3 (p > 0.05) (Figure 1).
Figure 1. Cont.
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Figure 1. Average percentage of cytosine-phosphate-guanine (CpG) methylation across the promoter
region and the percentage of methylation of each CpG unit within the promoter region of (A) Aqp1;
(B) Tfpi2; (C) Ampd3; and (D) Gatm in the female placentas from dams in the 1X and 4X choline groups.
Each CpG unit may contain more than one CpG site. Only CpG units with measurements that met the
quality control criteria were included in the final analyses. One placenta (either male or female) from
each dam (n = 3 dams per treatment, per fetal sex) was used, and each placenta was considered to be a
statistical unit in the statistical analysis. Data were analyzed using one-way ANOVA and are presented
as means with 95% confidence intervals. * p ≤ 0.05.
In the male placentas, six CpG units in the Dcn promoter met our quality control criteria and
were included in the analysis. Supplementation with 4X choline yielded higher (p = 0.022) methylation
of CpG unit D compared to 1X choline supplementation. In addition, trends for higher methylation
of CpG units B (p = 0.068) and K (p = 0.063), as well as average methylation in the promoter region
(p = 0.053) were detected in response to 4X choline supplementation. For Tnfrsf23, six CpG units in
the promoter region were analyzed. Among these CpG units, methylation of CpG unit F was higher
(p = 0.007) in the placentas of dams given 4X choline compared to those given 1X choline. Methylation
of CpG unit H also trended higher (p = 0.052) in the 4X choline placentas vs 1X choline placentas.
In contrast, the methylation in the Qpct promoter appeared unaffected (p > 0.05) by maternal choline
supplementation (Figure 2).
3.3. Placental Global DNA Methylation
Regardless of fetal sex, global placental DNA methylation was 21% higher (p = 0.015) in
the 4X choline group compared to the 1X choline group. In the female placentas, 4X choline
supplementation yielded higher (p = 0.035) global placental DNA methylation compared with 1X
choline supplementation. Global DNA methylation in the female placentas also positively correlated
with fetal weight and placental efficiency (fetal weight: β = 0.2, p =0.024; placental efficiency: β = 3.95,
p = 0.037). A numerically higher abundance of global DNA methylation was also detected in the male
placentas in response to 4X choline versus 1X choline (Figure 3); however, this numerical difference
did not achieve statistical significance (p = 0.086). No significant associations (p ≥ 0.16) were found
between global DNA methylation in male placentas and male fetal or placental outcomes.
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Figure 2. Average percentage of cytosine-phosphate-guanine (CpG) methylation across the promoter
region and percentage of methylation of each CpG unit within the promoter regions of (A) Qpct;
(B) Dcn and (C) Tnfrsf23 in male placentas from dams in the 1X and 4X choline groups. Each CpG
unit may contain more than one CpG site. Only CpG units with measurements that met the quality
control criteria were included in the final analyses. One placenta (either male or female) from each dam
(n = 3 dams per treatment, per fetal sex) was used, and each placenta was considered to be a statistical
unit in the statistical analysis. Data were analyzed using one-way ANOVA and are presented as means
with 95% confidence intervals. * p ≤ 0.05. # 0.05 < p < 0.1.
Figure 3. Percentage of global DNA methylation in the placentas from dams in the 1X and 4X choline
groups. One placenta (either male or female) from each dam (n = 3 dams per treatment, per fetal sex)
was used, and each placenta was considered to be a statistical unit in the statistical analysis. Data were
first analyzed without stratification by fetal sex and then separately for each fetal sex using one-way
ANOVA. Results are presented as means with 95% confidence intervals. * p ≤ 0.05. # p = 0.086.
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3.4. Placental miRNA Expression
Following data processing, 609 miRNAs were included in the final statistical analyses.
Among these miRNAs, the expression of miR-2137 was found to be significantly lower
(fold change = 0.3; FDR = 0.125, Punadjusted = 2.05 × 10−4) in response to 4X versus 1X maternal
choline supplementation. Although significance was not achieved upon stratification by fetal sex,
both female and male placentas from the 4X choline group exhibited lower expression of miR-2137
(fold change = 0.4 and 0.3, respectively). Based on TargetScan [28] prediction, miR-2137 has 170 mRNA
targets with context++ score≤−0.2. These mRNA targets are related to 11 biological processes (Table 3)
based on GO term analysis with PANTHER [31,32]. To determine if any of these predicted mRNA
targets were affected by placental reduction of miR-2137, their expression was assessed using the data
generated from the mRNA-sequencing experiment. Because the predicted mRNA targets constitute
only a small number of the genes listed on the mRNA sequencing dataset, mRNA targets with an
unadjusted p value of ≤ 0.05 are reported. The expression of five of the predicted mRNA targets was
higher in the female placentas supplemented with 4X choline compared to those supplemented with 1X
choline (Table 4). These included Cd109 (fold change = 1.55; p < 0.01), Mt3 (fold change = 3.85; p < 0.01),
Plg (fold change = 3.92; p < 0.01), Gja4 (fold change = 1.33; p = 0.01), and Psrc1 (fold change = 1.49;
p = 0.05). In the male placentas, 4X choline supplementation resulted in higher expression of four
of the predicted mRNA targets (Table 4), which were Pmaip1 (fold change = 1.39; p = 0.02), Pcdh1
(fold change = 1.25; p = 0.04), Mt3 (fold change = 1.69; p = 0.04), and Cd28 (fold change = 1.64; p = 0.05).
In contrast to the female placentas, the expression of Gja4 in the male placentas of 4X choline was
downregulated (fold change = 0.58; p < 0.01).
Table 3. Biological processes affected by the predicted mRNA targets of miR-2137 1.
Biological Processes p-Values
regulation of transcription from RNA polymerase II promoter (GO: 0006357) <0.01
transcription from RNA polymerase II promoter (GO: 0006366) <0.01
developmental process (GO: 0032502) <0.01
muscle organ development (GO: 0007517) 0.01
transcription, DNA-dependent (GO: 0006351) 0.01
segment specification (GO: 0007379) 0.01
nervous system development (GO: 0007399) 0.01
system development (GO: 0048731) 0.02
RNA metabolic process (GO: 0016070) 0.02
mesoderm development (GO: 0007498) 0.05
ectoderm development (GO: 0007398) 0.05
1 Predicted mRNA targets, which have a context++ score ≤−0.2, were obtained from TargetScan (Version 7.1) [28]
and were included in the gene ontology (GO) analysis. The gene ontology analysis was done using PANTHER
(Version 11.1) [31,32] with Bonferroni correction, and p ≤ 0.05 was considered statistically significant.
Table 4. Predicted mRNA targets of miR-2137 that displayed upregulation in the female and male
placentas in response to 4X choline supplementation 1−3.
Female
Placentas
Gene Symbol Gene Name Fold Difference
Gja4 gap junction protein, alpha 4 1.33
Psrc1 proline/serine-rich coiled-coil 1 1.49
Cd109 CD109 antigen 1.55
Mt3 metallothionein 3 3.85
Plg plasminogen 3.92
Male
Placentas
Pcdh1 protocadherin 1 1.25
Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 1.39
Cd28 CD28 antigen 1.64
Mt3 metallothionein 3 1.69
1 Predicted mRNA targets, which have a context++ score ≤−0.2, were obtained from TargetScan (Version 7.1) [28];
2 Fold change data were derived from an RNA-sequencing dataset, and statistical analysis was performed using
Cuffdiff (Cufflinks, Version 2.2) [25]; 3 Punadjusted ≤ 0.05 was considered to be significant.
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4. Discussion
To the best of our knowledge, this is the first study to survey the effects of maternal
choline supplementation on epigenetic markers in the mouse placenta in a genome-wide manner.
We demonstrated choline-induced sex-specific effects on imprinted gene expression patterns, some of
which are associated with changes in promoter region CpG dinucleotide methylation. We also showed
higher levels of global DNA methylation and suppression of miR-2137 abundance in placentas from
dams supplemented with additional choline during gestation.
4.1. Maternal Choline Supplementation Alters the Expression of Several Imprinted Genes in the Placenta
Placental expression of several imprinted genes was altered in a sex-specific manner in
response to higher maternal choline intake during gestation. In the female placentas, maternal
choline supplementation upregulated the expression levels of Gatm, Tfpi2, Aqp1 and Ampd3. Gatm
(glycine amidinotransferase) diverts glycine into the biosynthesis of creatine, which is a source of
energy for tissues with high energy needs. Lower expression of Gatm in the brain is associated with
mental and behavioral impairments whereas lower placental Gatm abundance is associated with
intrauterine growth restriction [38,39]. As such, the choline-induced upregulation in placental Gatm
abundance observed in the present study would be expected to improve fetal development. The other
choline-altered imprinted genes in the female placentas are implicated in processes essential to normal
placental vascular development and thereby also have the potential to affect fetal development.
Tfpi2 (tissue factor pathway inhibitor 2) inhibits the activity of matrix metalloproteinases and
regulates placental perfusion [40,41], while deficiency of Aqp1 (aquaporin 1) causes aberrant placental
vascularization and fetal overgrowth [37]. Although the consequences of altered expression of Ampd3
(AMP deaminase 3), a known regulator of fetal muscle and liver development [42], in the placenta
remain to be examined, Ampd3 deficiency in cancer cells has been shown to inhibit cell proliferation
and invasion [43]. Collectively, the choline-induced upregulation of all these placental imprinted
genes would be expected to improve placental vascularization and perfusion, likely contributing to
the choline-induced beneficial effects on placental transport efficiency and fetal development reported
previously [17].
The downregulation of the imprinted genes, Dcn (decorin) and Tnfrsf23 (tumor necrosis
factor receptor superfamily, member 23), in the male placentas in response to maternal choline
supplementation may also result in an improved placental vascular network. Dcn encodes a small
leucine-rich proteoglycan protein, and reduced placental Dcn expression enhances endothelial
cell migration and remodeling of the placental vasculature [44]. Tnfrsf23 is a receptor that
binds to the cytotoxic tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and its
downregulation may reduce apoptosis and modulate inflammatory responses during trophoblast
invasion [45,46]. Additionally, in the male placentas, 4X choline downregulated the abundance of Qpct
(glutaminyl cyclase), which controls placental nutrient delivery [47]. Upregulation of Qpct is frequently
detected in pre-eclamptic placentas [48], possibly as a compensatory response to poor placental
perfusion. Therefore, the choline-induced downregulation of Qpct in the present study may indicate
sufficiently perfused placentas, which is consistent with the previously reported choline-induced
enlargement of spiral arteries in the maternal decidua [17]. In sum, maternal choline supplementation
altered the abundance of placental imprinted genes in a manner that is consistent with previous reports
of choline-induced improvements in placental vascular development [17].
4.2. Altered Promoter-Region Methylation May Be One Epigenetic Mechanism Contributing to the
Choline-Induced Differential Expression of the Placental Imprinted Genes
As expected, lower promoter methylation occurred concurrently with the upregulation of Aqp1
and Tfpi2 expression in the choline-supplemented female placentas, whereas higher methylation
in the promoter regions occurred coincident with the downregulation of Dcn and Tnfrsf23 in
the choline-supplemented male placentas. However, higher methylation in the promoter of the
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upregulated Gatm was detected in the choline-supplemented female placentas. Although higher
methylation generally results in transcriptional repression, exceptions have been noted in several
genes where a methylated promoter still allows active gene transcription due to the presence of
other regulatory factors that coordinate with promoter methylation to modulate transcription [49].
Additionally, because the imprinting of Gatm is associated with an unmethylated CpG island in its
promoter region [50], the promoter hypermethylation observed in the present study may lead to a
loss of imprinting and transcriptional activation of both of its maternal and paternal alleles, resulting
in higher gene expression. Similarly, we observed that maternal choline supplementation altered
the placental expression of Qpct and Ampd3 without any noticeable changes in the methylation of
their promoters. We suggest that the transcriptional regulation of these genes may be independent of
promoter DNA methylation. A highly plausible explanation for the altered expression of these genes
could involve modifications of the histone proteins. Indeed, others have reported that increased Qpct
expression is associated with higher H3K4 methylation (e.g., H3K4me3) [47], whereas the expression
of Ampd3 is highly upregulated in mice depleted of Hdac3 [51], one of the enzymes responsible
for histone deacetylation that leads to a “closed” chromatin state and suppresses transcription.
Notably, we have previously shown that doubling the maternal choline intake during the third
trimester of human pregnancy alters global histone methylation and histone methyltransferase
abundance in the placenta [34]. Taken together, the choline-induced alterations in the expression
of the placental imprinted genes may be related to changes in the amount of methylation in different
key transcriptional regulators.
4.3. Maternal Choline Supplementation Increases Global DNA Methylation in the Placenta
Similar to our previous findings in humans [34], higher global DNA methylation in both female
and male placentas was found in response to additional maternal choline intake during pregnancy.
Global DNA hypomethylation often leads to genomic instability that increases mutation frequency
and disease susceptibility [52]. There is also a strong correlation between global DNA methylation
in the placenta and fetal growth outcomes, where a 10-point increase in birth weight percentile is
associated with 10% higher LINE-1 methylation (a surrogate marker of global DNA methylation)
in the human placenta [53]. Our regression analyses also support a similar positive relationship
between placental global DNA methylation with fetal body weight and placental efficiency in females.
In sum, the choline-induced increase in placental global DNA methylation found in this study is
expected to stabilize the placental genome, thereby minimizing any adverse effects on normal placental
development and ultimately improving fetal development.
4.4. Maternal Choline Supplementation Reduces Placental miR-2137 Abundance, with Downstream Effects on
the Expression of Its Potential Target Genes
Placental miR-2137 was downregulated by 4X choline supplementation in the present study.
Based on the bioinformatics analyses, miR-2137 targets genes that are important for development,
including the development of the mesodermal (GO: 0007498) and the ectodermal (GO: 0007398)
layers. These primary germ layers give rise to different body organs, including muscles, bones,
the cardiovascular system and the nervous system. Indeed, our bioinformatics analyses also indicated
that miR-2137 impacts the development of these organs (GO: 0007399 and GO: 0007517). These findings
not only support the proposed existence of a placental–brain axis and a placental–cardiovascular
axis [54], but may also explain the effects of prenatal choline supply on programming offspring
neurodevelopment [55] and normalizing the blood pressure of adult offspring from dams fed a
low-protein diet throughout gestation [56]. In addition, these data provide a possible mechanism
linking choline inadequacy to altered muscle membrane lipid composition and metabolism in mouse
muscle cells [57] as well as disrupted bone homeostasis and a lower bone mass in mice and linear
growth failure in young children [58,59]. Collectively, these data support the involvement of placental
miR-2137 in mediating the effect of maternal choline intake on various fetal developmental outcomes.
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Although miR-2137 has not been experimentally studied in the placenta, it has been examined in
other tissues [60–63]. Consistent with our bioinformatics analyses, these studies showed that altered
miR-2137 abundance changes the function of different organs, including the heart and the brain,
as well as processes related to cell signaling and apoptosis (both of which lost statistical significance
in our bioinformatics analyses upon adjustment for multiple testing). Interestingly, micronutrient
supplementation in a paternal undernutrition mouse model also changes miR-2137 expression in the
offspring pancreas [64], indicating that this miRNA may be particularly sensitive to nutritional status.
In addition to the bioinformatics analyses, we found that choline-induced miR-2137 downregulation
led to higher expression of several predicted mRNA targets. Despite being different between the female
and male placentas, these genes all play a role in the vascular development (e.g., Gja4 [65], Mt3 [66]
and Plg [67]), cell signaling (e.g., Cd109 [68] and Pcdh1 [69]) and apoptotic processes (e.g., Psrc1 [70],
Pmaip1 [71,72] and Cd28 [73]). These processes affect placental trophoblast survival and migration,
and the remodeling of the maternal vasculature, ultimately affecting normal placental morphological
and vascular development [74–76]. Taken together, changes induced by miR-2137 in response to a
higher maternal choline intake may benefit placental development and offspring health.
4.5. Study Limitations
Our study had several limitations. First, only three samples per condition were used in this
study; this was chosen based on tissue availability and conventional practices due to the uncertainty in
sample size calculation when small fold changes are expected [77]. This may have limited our ability
to detect additional placental imprinted genes and miRNAs that are developmentally important and
responsive to maternal choline supplementation. Another potential limitation is the underestimation
of the high variance in sequence reads distribution, which is likely due to the heterogeneity of
the placental tissues as each cell type may have its own discrete gene expression profile that can
confound the overall measurements. The issue of heterogeneity may also be relevant to the promoter
methylation experiments [78]. Additionally, the number and magnitude of change in promoter
methylation were relatively small, and their biological importance is currently unclear. It is possible
that higher magnitude changes in the methylation of other epigenetic regulators (e.g., histones) or
gene regions other than the promoter (e.g., the differential methylation region) are responsible for the
choline-induced expression changes [49]. Measurements of SAM, the methyl donor directly involved
in cellular methylation reactions, or choline metabolites in these placentas, may also provide additional
insight into the changes observed in this study. However, these markers were not examined in the
present study due to limited sample availability. With the exception of Tfpi2 [79], the imprinted genes
identified in the present study appear to be weakly imprinted in mouse placentas and may display
biallelic expression in human placentas [80–82]; therefore, the relevance of these findings to human
placentas is unknown. Although the pattern of differential gene expression appears to be sexually
dependent, the reasons and mechanisms accounting for this observation remain to be elucidated.
Because placental epigenetic markers are highly dependent on the developmental stage, it is also
possible that different results may be found on different gestational days.
5. Conclusions and Future Directions
Findings from the present study add to the growing body of research that illustrates
the responsiveness of the placental epigenome to maternal choline intake during pregnancy.
Although there are limitations associated with the exploratory nature of this work, it is an important
first step in elucidating the molecular mechanisms mediating some of the previously reported
choline-induced effects on placental and fetal development. Additional studies are needed to address
the functional effects of the placental epigenetic markers identified in this work, and to examine their
clinical relevance in predicting pregnancy outcomes and offspring health.
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